HilleVax Inc. is embroiled in a tumultuous situation following its acquisition by XOMA Royalty Corporation, with multiple law firms investigating potential breaches of fiduciary duty and securities law violations.

HilleVax, Inc. has been acquired by XOMA Royalty Corporation in a deal valued at $1.95 per share, expanding XOMA’s portfolio in the vaccine development space.

HilleVax Inc. has reported its quarterly earnings, showing a significant decline in stock price from its 52-week high, amidst market fluctuations and a complex financial landscape.